ImmunoCellular Therapeutics to Webcast, Live, at VirtualInvestorConferences.com December 3

Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com

NEW YORK, Dec. 1, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, President and Chief Executive Officer, will present live at VirtualInvestorConferences.com on December 3, 2015. Mr. Gengos plans to highlight the Company's ICT-107 phase 3 registrational program in patients with newly diagnosed glioblastoma and the Stem-to-T-cell research program.

DATE:   Thursday, December 3, 2015
TIME:    12:15p.m. ET/9:15a.m. PT
LINK: http://tinyurl.com/123pre

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

Learn more about the event: www.virtualinvestorconferences.com                           

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, is open for patient enrollment. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells.

About VirtualInvestorConferences.com
VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform. Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Logo - http://photos.prnewswire.com/prnh/20151201/292036LOGO

SOURCE ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd., Jane Green, 415.348.0010 direct, 415.652.4819 mobile, [email protected]; VirtualInvestorConferences.com, Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, [email protected], http://www.virtualinvestorconferences.com